Table 7.

Resource-stratified recommendations for the treatment of castration-resistant prostate cancer

Resource-level	Asymptomatic mCRPC	Symptomatic mCRPC	Second-line mCRPC	Third-line mCRPC
Basic/limited	Docetaxel	Docetaxel	Docetaxel re-challenge in selected patients Supportive care	Supportive care
Enhanced/maximal	Abiraterone/enzalutamide Docetaxel	Docetaxel Abiraterone/enzalutamide	Docetaxel/cabazitaxel Abiraterone/Enzalutamide Consider biopsy—if low PSA/visceral disease	Cabazitaxel Consider biopsy—if low PSA/visceral disease Consider PSMA-based theranostics if available